Perspectives on COVID-19 Vaccine and Therapeutic Development from Tufts Center for the Study of Drug Development

BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Experts from the Tufts Center for the Study of Drug Development are available to provide objective analysis and commentary on the nature and pace of development of vaccines and therapeutics to prevent and treat COVID-19.

Examples:

  • R&D challenges in vaccine development
  • Cost of drug development
  • Duration of clinical trials and regulatory approval times
  • The changing nature of clinical trials, e.g., use of real world evidence and data, virtual clinical trials
  • Protocol complexity in clinical trials
  • Clinical trial success rates
  • Challenges of clinical trials, e.g., patient recruitment, retention, and demographics; clinical site initiation; data management
  • FDA-sanctioned regulatory frameworks for expediting drug development to meet urgent medical needs
  • Other FDA policies and procedures that can affect drug development speed
  • R&D challenges in developing drugs for rare diseases  
  • Academic-industry collaboration on new drug development
  • Industry adoption of artificial intelligence and machine learning in drug discovery and development
  • Issues related to ensuring new drug safety and efficacy

Experts available:

Kenneth I Kaitin, PhD, Professor and Director of Tufts CSDD
Cell: 781-771-7729  Email: kenneth.kaitin@tufts.edu

Ken Getz, MBA, Professor and Deputy Director of Tufts CSDD
Cell: 617-590-4175  Email: kenneth.getz@tufts.edu

Joseph A. DiMasi, PhD, Research Associate Professor and Director of Economic Analysis
Cell: 617-777-4402  Email: joseph.dimasi@tufts.edu

Mary Jo Lamberti, PhD, Research Assistant Professor and Associate Director of Sponsored Research
Cell: 781-820-2613  Email: mary_jo.lamberti@tufts.edu

ABOUT THE TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT

The Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the efficiency and productivity of pharmaceutical R&D. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes Tufts CSDD Impact Reports, a bi-monthly newsletter providing analysis and insight into critical drug development issues.

Contacts:Tufts University
 Luna Rodriguez – 617-636-2170
 Luna.Rodriguez@tufts.edu
  
 Business Communication Strategies
 Peter Lowy – 617-734-9980
 lowy@bus-com.com